Disease · MONDO_0006952
retinopathy of prematurity
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. retinopathy of prematurity. Diseases, record MONDO_0006952. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006952
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- ROP, Retinopathy of prematurity (disorder), Retrolental fibroplasia (disorder), Terry syndrome, premature retinopathy, retrolental fibroplasia
- Open Targets
Drugs22
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Phase 3 | ClinicalTrials.gov | 11 | 11 | 11 | Drugs and targets |
| RANIBIZUMAB | CHEMBL1201825 | Antibody | Phase 3 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
| AFLIBERCEPT | CHEMBL1742982 | Protein | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| PHENYLEPHRINE | CHEMBL1215 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| TROPICAMIDE | CHEMBL1200604 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| LEVOTHYROXINE | CHEMBL1624 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PROPRANOLOL | CHEMBL27 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| FASUDIL | CHEMBL38380 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ACETAMINOPHEN | CHEMBL112 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| BLOOD CELLS, RED | CHEMBL2108195 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 22
See all 22 drugsTargets36
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| VEGFA | Vascular endothelial growth factor A, long form | 4 | Vascular endothelial growth factor A inhibitor | Phase 3 | https://conductscience.org/library/genes/7422 | Drugs and targets |
| EPOR | Erythropoietin receptor | 3 | Erythropoietin receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/2057 | Drugs and targets |
| PGF | Placenta growth factor | 2 | Placenta growth factor inhibitor | Phase 3 | https://conductscience.org/library/genes/5228 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 2 | Cyclooxygenase inhibitor | Phase 2 | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 2 | Cyclooxygenase inhibitor | Phase 2 | https://conductscience.org/library/genes/5743 | Drugs and targets |
| ROCK1 | Rho-associated protein kinase | 2 | Rho-associated protein kinase inhibitor | Phase 2/3 | https://conductscience.org/library/genes/6093 | Drugs and targets |
| ROCK2 | Rho-associated protein kinase | 2 | Rho-associated protein kinase inhibitor | Phase 2/3 | https://conductscience.org/library/genes/9475 | Drugs and targets |
| ADRA1A | Adrenergic receptor alpha-1 | 1 | Adrenergic receptor alpha-1 agonist | Phase 3 | https://conductscience.org/library/genes/148 | Drugs and targets |
| ADRA1B | Adrenergic receptor alpha-1 | 1 | Adrenergic receptor alpha-1 agonist | Phase 3 | https://conductscience.org/library/genes/147 | Drugs and targets |
| ADRA1D | Adrenergic receptor alpha-1 | 1 | Adrenergic receptor alpha-1 agonist | Phase 3 | https://conductscience.org/library/genes/146 | Drugs and targets |
1 to 10 of 36
See all 36 targetsTrials46
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02375971 | RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity | Phase 3 | 224 | 2018-07-31 | Retinopathy of Prematurity | RANIBIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02640664 | Rainbow Extension Study | Phase 3 | 180 | 2023-02-13 | Retinopathy of Prematurity (ROP) | RANIBIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00622726 | Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity | Phase 2 | 150 | 2014-06-09 | Retinopathy of Prematurity | BEVACIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04101721 | Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity | Phase 3 | 127 | 2023-07-20 | Retinopathy of Prematurity | AFLIBERCEPT | Its record names the disease | ClinicalTrials.gov |
| NCT01030575 | Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2) | Phase 2 | 125 | 2021-03-12 | Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Bronchopulmonary Dysplasia (BPD) | INOSITOL | Its record names the disease | ClinicalTrials.gov |
| NCT02390531 | Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity | Phase 1 | 120 | 2022-11-03 | Retinopathy of Prematurity | BEVACIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04004208 | Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy | Phase 3 | 113 | 2022-05-06 | Retinopathy of Prematurity (ROP) | AFLIBERCEPT | Its record names the disease | ClinicalTrials.gov |
| NCT01238471 | Oral Propranolol Versus Placebo for Early Stages of Retinopathy of Prematurity: A Randomized and Prospective Study | Phase 1/2 | 20 | 2014-06-10 | Retinopathy of Prematurity | PROPRANOLOL, SUCROSE | Its record names the disease | ClinicalTrials.gov |
| NCT04634604 | A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP | Phase 3 | 16 | 2024-08-01 | Retinopathy of Prematurity | BEVACIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT06775353 | To Assess the Effect of Dexamethasone Eye Drops on the Retinopathy of Prematurity Outcome | 2,017 | Retinopathy of Prematurity (ROP) | DEXAMETHASONE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 46
See all 46 trialsComparisons in its trials9
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Bevacizumab for ROP-Experimental Arm vs Conventional Laser for ROP-Control Arm: serious adverse events | 0 of 69 | 0 of 68 | 137 | NCT00622726 | Trial comparisons |
| Laser Photocoagulation vs Aflibercept 0.4 mg: deaths from any cause | 0 of 27 | 1 of 93 | 120 | NCT04101721 | Trial comparisons |
| Laser Photocoagulation vs Aflibercept 0.4 mg: serious adverse events | 12 of 27 | 32 of 93 | 120 | NCT04101721 | Trial comparisons |
| Aflibercept 0.4 mg vs Laser Photocoagulation: deaths from any cause | 3 of 75 | 0 of 38 | 113 | NCT04004208 | Trial comparisons |
| Aflibercept 0.4 mg vs Laser Photocoagulation: serious adverse events | 9 of 75 | 10 of 38 | 113 | NCT04004208 | Trial comparisons |
| Propranolol vs Oral Sucrose 5%: serious adverse events | 0 of 10 | 0 of 10 | 20 | NCT01238471 | Trial comparisons |
| Bevacizumab vs Laser: deaths from any cause | 0 of 7 | 0 of 9 | 16 | NCT04634604 | Trial comparisons |
| Bevacizumab vs Laser: serious adverse events | 1 of 7 | 4 of 9 | 16 | NCT04634604 | Trial comparisons |
| Bevacizumab vs Laser: Treatment Success Rate At 6 Months Adjusted Age | 3 of 3 | 4 of 5 | 8 | NCT04634604 | Trial comparisons |
Papers from its trials33
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006952
GET https://conductscience.org/api/diseases/v1/MONDO_0006952/drugs?page=2